NeoMatrix Gets Series C

Irvine-based NeoMatrix, a developer of breast cancer screening tests, said earlier this week that it has closed a Series C round of equity financing. Amount of the funding was not given. NeoMatrix is developing a screening test which looks for atypical ductal hyperplasia (ADH), a biomarker that is a precursor to breast cancer. No further details of the funding were released. More information »